Citations

Clear

19 citation(s) found for "Park, David".

Global Variations in Practices After Bariatric and Metabolic Surgery; the PARTNER study
Clyde, Danielle , Grant, Callum, Canales, Juan Andres Aguiar, Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Goodpaster, Kasey , Hopkins, George, Jatana, Anita , Kothari, Shanu N. , Kow, Lillian, Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Ratcliffe, Denise , Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Voon, Kelvin , Lamb, Peter , Mahawar, Kamal , Grant, Callum, Canales, Juan Andres Aguiar, Cameron, David, Copăescu, Cătălin , Clare, Ken , Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Hazebroek, Eric J. , Husain, Farah Anwari , Joyce, Brian, Kermansaravi, Mohammad , Miras, Alexander Dimitri , Moizé, Violeta , Neto, Manoel Galvão , Peterli, Ralph , Sakran, Nasser , Salminen, Paulina , Singhal, Rishi , Stenberg, Erik , Tahrani, Abd A. , Vilallonga, Ramón , Welbourn, Richard , Zerrweck, Carlos , Moussa, Osama , Byrne, James Patrick , Parmar, Chetan D. , Ghanem, Omar M. , Robertson, Andrew G. , Yang, Wah

Mayo Clinic

No container title available | August 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6779565/v1 Get It

Abstract Background: With over 1 billion individuals affected globally, obesity and obesity related diseases is now a leading cause of death. Metabolic and bariatric surgery (MBS) has emerged as a cornerstone intervention for severe obesity and its associated comorbidities. Despite its efficacy, postoperative care and follow-up after MBS remains highly variable worldwide. Objective: The PARTNER study aimed to evaluate global clinical practices in the postoperative management following MBS by surveying multidisciplinary healthcare professionals . Methods: This study was an international online survey conducted between October 2024 and January 2025. A multidisciplinary team developed the questionnaire based on existing literature and international guidelines. The survey assessed five domains: follow-up care, postoperative treatment, dietary management, patient support, and measurement of surgical outcomes. Responses were analysed descriptively. Results: A total of 262 responses were received from 62 countries. Most respondents were bariatric surgeons (72.1%) working in public healthcare systems (73.3%). While 78.7% reported conducting three-month postoperative reviews, only 23.7% offered indefinite follow-up. Hybrid models of care (virtual and in-person) were common (56.9%). VTE prophylaxis and postoperative PPI use were recommended by 64.1% and 84.3% respectively. Nearly all respondents (98.1%) provided dietary advice, with protein and micronutrient supplementation widely endorsed. Only 56.1% routinely referred patients for psychological follow-up. Definitions of surgical success and failure varied widely, with inconsistent objective outcome measures. Conclusion: The PARTNER study reveals significant international variation in postoperative management practices following MBS. These findings underscore the need for more standardized, evidence-based guidelines to improve long-term outcomes and equity of care worldwide.
An international Delphi consensus on patient preparation for metabolic and bariatric surgery
Clyde, Danielle , Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Catalain, Copaescu, Clare, Ken , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Ghanem, Omar M. , Hopkins, George, Kothari, Shanu N. , Kow, Lilian , Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Saliminen, Paulina, Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Tahrani, Abd A. , Voon, Kelvin , Welbourn, Richard , Lamb, Peter , Mahawar, Kamal , Yang, Wah , Salminen, Paulina , Kermansaravi, Mohammad , Zerrweck, Carlos , Yang, Wah , Byrne, James Patrick , Cameron, David, Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Husain, Farah Anwari , Joyce, Brian, Miras, Alexander Dimitri , Moussa, Osama , Neto, Manoel Galvão , Parmar, Chetan D. , Peterli, Ralph , Stenberg, Erik , Vilallonga, Ramón , Robertson, Andrew G.

Mayo Clinic

Clinical Obesity | December 14, 2024 | Volume: 15 | Issue: 2 | Pages: No page available

10.1111/cob.12722 | PMID 39673462 Get It

SummaryGlobal obesity rates have risen dramatically, now exceeding deaths from starvation. Metabolic and bariatric surgery (MBS), initially for severe obesity (BMI ≥35 kg/m2), is performed globally over 500 000 times annually, offering significant metabolic benefits beyond weight loss. However, varying eligibility criteria globally impact patient care and healthcare resources. Updated in 2022, ASMBS and IFSO guidelines aim to standardise MBS indications, reflecting current understanding and emphasising comprehensive preoperative assessments. Yet, clinical variability persists, necessitating consensus‐based recommendations. This modified Delphi study engaged 45 global experts to establish consensus on perioperative management in MBS. Experts selected from bariatric societies possessed expertise in MBS and participated in a two‐round Delphi protocol. Consensus was achieved on 90 of 169 statements (53.3%), encompassing multidisciplinary team composition, patient selection criteria, preoperative testing, and referral pathways. The agreement highlighted the critical role of comprehensive preoperative assessments and the integration of healthcare professionals in MBS. These findings offer essential insights to standardise perioperative practices and advocate for evidence‐based guidelines in MBS globally. The study underscores the need for unified protocols to optimise outcomes and guide future research in MBS.
Artificial Intelligence–Enabled Stool Analysis for Lactulose Titration Assistance in Hepatic Encephalopathy Through a Smartphone Application
Chara, Beatriz Sordi , Hara, Kamalpreet S. , Schmidt, Kathryn A. , Kassmeyer, Blake A., Anstey, Jacob, Tiede, David, Kamath, Patrick S. , Shah, Vijay H. , Bajaj, Jasmohan S. , Kraus, Asaf, Sordi Chara, Beatriz , Penrice, Daniel , Kamath, Patrick S , Bajaj, Jasmohan S , Penrice, Daniel D. , Simonetto, Douglas A.

Mayo Clinic

American Journal of Gastroenterology | January 19, 2024 | Volume: 119 | Issue: 5 | Pages: 982-986

10.14309/ajg.0000000000002656 | PMID 38240303 Get It

INTRODUCTION: Management of hepatic encephalopathy relies on self-titration of lactulose. In this feasibility trial, we assess an artificial intelligence–enabled tool to guide lactulose use through a smartphone application. METHODS: Subjects with hepatic encephalopathy on lactulose captured bowel movement pictures during lead-in and intervention phases. During the intervention phase, daily feedback on lactulose titration was delivered through the application. Goals were determined according to number of bowel movement and Bristol Stool Scale reports. RESULTS: Subjects completed the study with more than 80% satisfaction. In the lead-in phase, less compliant subjects achieved Bristol Stool Scale goal on 62/111 (56%) of days compared with 107/136 (79%) in the intervention phase ( P = 0.041), while the most compliant subjects showed no difference. Severe/recurrent hepatic encephalopathy group achieved Bristol Stool Scale goal on 80/104 (77%) days in the lead-in phase and 90/110 (82%) days in the intervention phase ( P = NS), compared with 89/143 (62%) days and 86/127 (68%) days in the stable group. DISCUSSION: Dieta application is a promising tool for objective Bowel Movement/Bristol Stool Scale tracking for hepatic encephalopathy and may potentially be used to assist with lactulose titration.
Artificial Intelligence Evaluation of Stool Quality Guides Management of Hepatic Encephalopathy Using a Smartphone App
Fagan, Andrew , Gallagher, Mary Leslie, Mousel, Travis, Davis, Brian , Puri, Puneet, Anstey, Jacob, Tiede, David, Kraus, Asaf, Bajaj, Jasmohan S. , Bajaj, Jasmohan S , Fuchs, Michael A. , Puri, Puneet, Simonetto, Douglas A.

Mayo Clinic

American Journal of Gastroenterology | December 28, 2023 | Volume: 119 | Issue: 5 | Pages: 977-981

10.14309/ajg.0000000000002646 | PMID 38153339 Get It

Lactulose-based hepatic encephalopathy treatment requires bowel movements/day titration, which is improved with Bristol stool scale (BSS) incorporation. Dieta app evaluates artificial intelligence (AI)-based BSS (AI-BSS) with stool images. Initially, controls (N = 13) and cirrhosis patients on lactulose/not on lactulose (n = 33) were trained on the app. They entered self-reported BSS (self-BSS) with AI-BSS communicated. Lactulose dose changes were tracked. A subset (n = 12) was retested with AI communication blocked. Most subjects were comfortable with the app. Self/AI-BSS and lactulose dose/AI-BSS correlation increased with app use. AI-BSS communications improved insight into self-BSS over time. Dieta app to gauge stool AI characteristics was acceptable and increased insight into lactulose dose and BSS in cirrhosis.
Advances in Cardiac Electrophysiology
Piccini, Jonathan P. , Russo, Andrea M. , Sharma, Parikshit S. , Kron, Jordana , Tzou, Wendy S. , Sauer, William H. , Park, David , Birgersdotter‐Green, Ulrika , Frankel, David S. , Healey, Jeff S. , Linz, Dominik , Wißner, Erik , Zeitler, Emily P. , Wang, Paul J. , Tzou, Wendy , Park, David S , Hummel, John , Koruth, Jacob , Linz, Dominik , Mittal, Suneet , Nair, Devi G , Nattel, Stanley , Noseworthy, Peter A , Steinberg, Benjamin A , Trayanova, Natalia A , Wan, Elaine Y , Wissner, Erik , Zeitler, Emily P , Wang, Paul J , Healey, Jeffrey S , Hummel, John D. , Noseworthy, Peter A. , Steinberg, Benjamin A. , Trayanova, Natalia A. , Wan, Elaine Y.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | November 28, 2022 | Volume: 15 | Issue: 12 | Pages: No page available

10.1161/circep.121.009911 | PMID 36441565 Get It

Despite the global COVID-19 pandemic, during the past 2 years, there have been numerous advances in our understanding of arrhythmia mechanisms and diagnosis and in new therapies. We increased our understanding of risk factors and mechanisms of atrial arrhythmias, the prediction of atrial arrhythmias, response to treatment, and outcomes using machine learning and artificial intelligence. There have been new technologies and techniques for atrial fibrillation ablation, including pulsed field ablation. There have been new randomized trials in atrial fibrillation ablation, giving insight about rhythm control, and long-term outcomes. There have been advances in our understanding of treatment of inherited disorders such as catecholaminergic polymorphic ventricular tachycardia. We have gained new insights into the recurrence of ventricular arrhythmias in the setting of various conditions such as myocarditis and inherited cardiomyopathic disorders. Novel computational approaches may help predict occurrence of ventricular arrhythmias and localize arrhythmias to guide ablation. There are further advances in our understanding of noninvasive radiotherapy. We have increased our understanding of the role of His bundle pacing and left bundle branch area pacing to maintain synchronous ventricular activation. There have also been significant advances in the defibrillators, cardiac resynchronization therapy, remote monitoring, and infection prevention. There have been advances in our understanding of the pathways and mechanisms involved in atrial and ventricular arrhythmogenesis.
Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and Guidelines
Vance, Gail H. , Barry, Todd, Bloom, Kenneth J., Hicks, David G., Jenkins, Robert B. , Persons, Diane L., Tubbs, Raymond R., Hammond, M. Elizabeth H. , Fitzgibbons, Patrick L.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 12, 2021 | Volume: 133 | Issue: 4 | Pages: 611-612

10.5858/133.4.611 | PMID 19391661 Get It

Abstract Context. —Intratumoral heterogeneity of HER2 gene amplification has been well documented and represents subclonal diversity within the tumor. The reported incidence of intratumor HER2 amplification genetic heterogeneity ranges in the literature from approximately 5% to 30%. The presence of HER2 genetic heterogeneity may increase subjectivity in HER2 interpretation by the pathologist. Objectives. —To define HER2 genetic heterogeneity and to provide practice guidelines for examining and reporting breast tumors with genetic heterogeneity for improvement of HER2 testing in breast cancer. Design. —We convened an expert panel to discuss HER2 gene amplification testing by fluorescence in situ hybridization. Components addressed included a definition of HER2 amplification heterogeneity, practice guidelines for examination of the tissue, and reporting criteria for this analysis. Results. —Genetic heterogeneity for amplification of HER2 gene status in invasive breast cancer is defined and guidelines established for assessing and reporting HER2 results in these cases. These guidelines are additive to and expand those published in 2007 by the American Society of Clinical Oncology and the College of American Pathologists. Conclusion. —Standardized methods for analysis will improve the accuracy and consistency of interpretation of HER2 gene amplification status in breast cancer.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Andrews, Stephanie, Armand, Philippe , Davies, Marianne, Dunnington, David, Frigault, Matthew J. , Kaffenberger, Benjamin H. , Lunning, Matthew A. , McGettigan, Suzanne , McPherson, Jordan P. , Mohindra, Nisha , Naidoo, Jarushka , Olszanski, Anthony J. , Oluwole, Olalekan O. , Patel, Sandip Pravin , Reddy, Sunil , Ryder, Mabel , Santomasso, Bianca , Shofer, Scott , Sosman, Jeffrey A. , Weight, Ryan , Johnson-Chilla, Alyse, Zuccarino-Catania, Griselda, Engh, Anita M. , Oluwole, Olalekan O , Naidoo, Jarushka , Olszanski, Anthony J , Kaffenberger, B , Ryder, Mabel , Bhatia, Shailender , Budde, Lihua E. , Costa, Luciano J. , Ernstoff, Marc S. , Pennell, Nathan A , Wang, Yinghong

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 5, 2020 | Volume: 18 | Issue: 3 | Pages: 230-241

10.6004/jnccn.2020.0012 | PMID 32135517 Get It

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.
Acellular Biologic Nipple–Areolar Complex Graft: In Vivo Murine and Nonhuman Primate Host Response Evaluation
Pashos, Nicholas C. , Graham, David M. , Burkett, Brian J. , O’Donnell, Benjamen , Sabol, Rachel A. , Helm, Joshua, Martin, Elizabeth C. , Bowles, Annie C. , Heim, William M., Caronna, Vince C., Miller, Kristin S. , Grasperge, Brooke , Sullivan, Scott K., Chaffin, Abigail E. , Burkett, Brian , Caronna, Vincent C., Bunnell, Bruce A.

Mayo Clinic

Tissue Engineering Part A | January 17, 2020 | Volume: 26 | Issue: 15-16 | Pages: 872-885

10.1089/ten.tea.2019.0222 | PMID 31950890 Get It

Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine
Compton, Carolyn C. , Robb, James A., Anderson, Matthew W. , Berry, Anna B. , Birdsong, George , Bloom, Kenneth J., Branton, Philip A. , Crothers, Jessica W. , Cushman‐Vokoun, Allison M. , Hicks, David G., Khoury, Joseph D. , Laser, Jordan , Marshall, Carrie B. , Misialek, Michael J., Natale, Kristen E. , Nowak, Jan A. , Olson, Damon R. , Pfeifer, John D. , Schade, Andrew E., Vance, Gail H. , Walk, Eric , Yohe, Sophia , Birdsong, George G, Nowak, Jan Anthony, Olson, Damon, Schade, Andrew, Walk, Eric E, Yohe, Sophia Louise, Berry, Anna , Olson, Damon R

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 22, 2019 | Volume: 143 | Issue: 11 | Pages: 1346-1363

10.5858/arpa.2019-0009-sa | PMID 31329478 Get It

Biospecimens acquired during routine medical practice are the primary sources of molecular information about patients and their diseases that underlies precision medicine and translational research. In cancer care, molecular analysis of biospecimens is especially common because it often determines treatment choices and may be used to monitor therapy in real time. However, patient specimens are collected, handled, and processed according to routine clinical procedures during which they are subjected to factors that may alter their molecular quality and composition. Such artefactual alteration may skew data from molecular analyses, render analysis data uninterpretable, or even preclude analysis altogether if the integrity of a specimen is severely compromised. As a result, patient care and safety may be affected, and medical research dependent on patient samples may be compromised. Despite these issues, there is currently no requirement to control or record preanalytical variables in clinical practice with the single exception of breast cancer tissue handled according to the guideline jointly developed by the American Society of Clinical Oncology and College of American Pathologists (CAP) and enforced through the CAP Laboratory Accreditation Program. Recognizing the importance of molecular data derived from patient specimens, the CAP Personalized Healthcare Committee established the Preanalytics for Precision Medicine Project Team to develop a basic set of evidence-based recommendations for key preanalytics for tissue and blood specimens. If used for biospecimens from patients, these preanalytical recommendations would ensure the fitness of those specimens for molecular analysis and help to assure the quality and reliability of the analysis data.
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Andrews, Stephanie, Armand, Philippe , Davies, Marianne, Dunnington, David, Frigault, Matthew J. , Hoffner, Brianna, Lunning, Matthew A. , Mohindra, Nisha , Naidoo, Jarushka , Olszanski, Anthony J. , Oluwole, Olalekan O. , Patel, Sandip Pravin , Reddy, Sunil , Ryder, Mabel , Santomasso, Bianca , Shofer, Scott , Sosman, Jeffrey A. , Wahidi, Momen M. , Johnson-Chilla, Alyse, Scavone, Jillian L., Oluwole, Olalekan O , Naidoo, Jarushka , Olszanski, Anthony J , Ryder, Mabel , Bhatia, Shailender , Budde, Lihua E. , Costa, Luciano J. , Ernstoff, Marc S. , Hoimes, Christopher , Lacouture, Mario E. , Locke, Frederick L. , Wang, Yinghong

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 20, 2019 | Volume: 17 | Issue: 3 | Pages: 255-289

10.6004/jnccn.2019.0013 | PMID 30865922 Get It

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org .